Jiménez-Vicente, C., Esteve, J., Baile-González, M., Pérez-López, E., Calvo, C., Aparicio, C., . . . Salas, M. (2025). Allo-HCT refined ELN 2022 risk classification: Validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC).
Citación estilo ChicagoJiménez-Vicente, C., et al. Allo-HCT Refined ELN 2022 Risk Classification: Validation of the Adverse-Plus Risk Group in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC). 2025.
Cita MLAJiménez-Vicente, C., et al. Allo-HCT Refined ELN 2022 Risk Classification: Validation of the Adverse-Plus Risk Group in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation Within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC). 2025.